‘. Several patients in our institution were enrolled and I am ‘encouraged very satisfied with the results so far, said Dr. James Gladstone, associate Professor of Orthopaedics at Mount Sinai School of Medicine in New York City and investigators in the clinical trial. ‘orthopedists have long wanted to generate a secure, long-term solution for the regeneration of articular cartilage injuries with real instead of fibrocartilage by the microfracture procedure. The BioCart system is exciting technology as it uses its own to restore its to restore their quality-of-life. ‘.
Fibrocartilage not usually stand up over time and demoralized usually after a few years, and may need to repeat a task. Rehabilitation a lengthy process, often reach up to a year under the full mobility.
ProChon Biotech expands U.S. The randomized, double-arm, multicenter phase II study to compare the safety and efficacy of the BioCart system for the treatment of symptomatic cartilage defects microfracture. ProChon , ten clinical sites in the U.S. And Israel to have by the end of this year. – ‘The expansion of the BioCart clinical program an important step towards validating the potential of this promising technology is,’said Patrick O’Donnell, chief executive officer of ProChon. ‘We believe that the technology BioCart some of the main limitations microfracture procedure as well as current generation autologous cartilage cell transplantation technologies addressed connected.Of the Aristotle study investigates apixaban Compare on in about 15,000 AF Patients, warfarin. The AVERROES study investigated apixaban comparison with aspirin to approximately 5,600 patients with atrial fibrillation who are not a of vitamin K antagonist the treatment or is does not returns VKA therapy was well tolerated.. Apixaban has and in phase of III studies examining the preventing stroke and other thromboembolic events in patients having atrial fibrillation and to study the treatment of VTE.
The assembled efficacy endpoint was the times of patient randomization to the first appearance a combination of the Herz – circulation event including cardiovascular death of, non-fatal myocardial infarction, severe recurrent ischemia and non – hemorrhagic stroke.
A further description of risks and uncertainties, in the Pfizer’s Annual Report on Form 10 – K for its year ending 31 December 2007, and to find in its reports on Form 10-Q and Form 8-K..